Insulet Corporation (NASDAQ:PODD) Shares Bought by Bogart Wealth LLC

Bogart Wealth LLC boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 64.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,823 shares of the medical instruments supplier's stock after acquiring an additional 15,188 shares during the quarter. Bogart Wealth LLC owned about 0.06% of Insulet worth $10,195,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Itau Unibanco Holding S.A. acquired a new stake in Insulet during the fourth quarter worth $42,000. Golden State Wealth Management LLC boosted its position in shares of Insulet by 553.1% during the first quarter. Golden State Wealth Management LLC now owns 209 shares of the medical instruments supplier's stock worth $55,000 after buying an additional 177 shares during the period. Assetmark Inc. boosted its position in shares of Insulet by 1,447.1% during the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after buying an additional 246 shares during the period. Coppell Advisory Solutions LLC boosted its position in shares of Insulet by 135.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 282 shares of the medical instruments supplier's stock worth $74,000 after buying an additional 162 shares during the period. Finally, MassMutual Private Wealth & Trust FSB boosted its position in shares of Insulet by 23.1% during the first quarter. MassMutual Private Wealth & Trust FSB now owns 314 shares of the medical instruments supplier's stock worth $82,000 after buying an additional 59 shares during the period.

Analyst Upgrades and Downgrades

Several research firms have recently commented on PODD. Wolfe Research upgraded Insulet from a "peer perform" rating to an "outperform" rating and set a $350.00 price target for the company in a research report on Tuesday, May 13th. Truist Financial initiated coverage on Insulet in a research report on Monday, June 16th. They set a "buy" rating and a $365.00 price target for the company. Citigroup reiterated a "buy" rating on shares of Insulet in a report on Tuesday, July 8th. Raymond James Financial reiterated an "outperform" rating and issued a $360.00 target price (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Finally, Wells Fargo & Company set a $322.00 target price on Insulet in a report on Monday, April 28th. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $321.00.

Insider Transactions at Insulet

In related news, SVP John W. Kapples sold 5,278 shares of the business's stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $318.47, for a total value of $1,680,884.66. Following the transaction, the senior vice president owned 23,180 shares in the company, valued at $7,382,134.60. The trade was a 18.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.39% of the stock is owned by company insiders.

Insulet Stock Down 2.7%

PODD opened at $289.32 on Monday. The business's 50-day simple moving average is $307.29 and its 200-day simple moving average is $280.25. The company has a debt-to-equity ratio of 1.21, a quick ratio of 3.63 and a current ratio of 4.47. Insulet Corporation has a one year low of $173.00 and a one year high of $329.33. The stock has a market capitalization of $20.36 billion, a P/E ratio of 52.04, a price-to-earnings-growth ratio of 2.58 and a beta of 1.35.

Insulet (NASDAQ:PODD - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.02 EPS for the quarter, topping analysts' consensus estimates of $0.81 by $0.21. Insulet had a return on equity of 22.25% and a net margin of 18.29%. The business had revenue of $569.00 million for the quarter, compared to analysts' expectations of $543.20 million. During the same quarter in the previous year, the firm earned $0.73 earnings per share. The business's revenue was up 28.8% compared to the same quarter last year. Analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.